Karnataka sets 24-hr deadline for Cipla, Jubilant to supply Remdesivir
Roche India on Monday announced the rollout of its first batch of the antibody cocktail (Casirivimab and Imdevimab) against Coronavirus in India. The cocktail drug will be marketed by Cipla pan-India.
The second batch of the cocktail jabs will be made available by mid-June. Together, they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients, the company said in a statement.
The price for each patient dose [a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750. The maximum retail price for the multi-dose pack (each pack can treat two patients) is Rs 119,500, the statement added.
Cipla introduces RT-PCR test kit ViraGen in Indian market: All you need to know
ViraGen is Cipla s third offering in the Covid-19 testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits.
Share
Updated: May 25, 2021, 07:59 PM IST
A real-time Covid-19 testing kit, launched last week by drug major Cipla, will be in the market from Tuesday, the company said. The polymerase chain reaction (RT-PCR) test kit is called ViraGen and is manufactured for the country by the company in partnership with Ubio Biotechnology Systems.
ViraGen is Cipla s third offering in the Covid-19 testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits.
URL copied
Roche s Covid antibody cocktail launched in India for treatment of mild to moderate cases
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.
Roche s COVID-19 antibody cocktail launched in India at Rs 59,750 per dose
Antibody cocktail is to be administered for treatment of mild to moderate coronavirus disease in adults and pediatric patients who are confirmed to be infected with SARS-COV2 and are at high risk of developing severe COVID-19 disease and do not require oxygen
BusinessToday.In | May 24, 2021 | Updated 11:41 IST
Cocktail has been shown to help high-risk Covid patients before their condition worsens
Roche India and Cipla Limited, in a joint statement today, said the first batch of the antibody cocktail Casirivimab and Imdevimab is now available in India, while a second batch will be made available by mid-June. The price for each patient dose, a combined dose of 1,200 mg (600 mg of Casirivimab and 600 mg of Imdevimab), will be Rs 59,750, inclusive of all taxes. The MRP for the multi dose pack, each pack can treat two patients, is Rs 119,500.